0
     

Report Added
Report already added
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

According to the recently published report 'Histone Deacetylase 6 - Drugs In Development, 2022'; Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) pipeline Target constitutes close to 53 molecules. Out of which approximately 44 molecules are developed by companies and remaining by the universities/institutes.

Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Histone deacetylase 6 is an enzyme encoded by the HDAC6 gene. Histone deacetylation gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events. Histone deacetylases plays a central role in microtubule-dependent cell motility via deacetylation of tubulin. It is involved in the MTA1-mediated epigenetic regulation of ESR1 expression in breast cancer. It plays a key role in the degradation of misfolded proteins. It acts as an adapter that recognizes polyubiquitinated misfolded proteins and target them to the aggresome, facilitating their clearance by autophagy.

The report 'Histone Deacetylase 6 - Drugs In Development, 2022' outlays comprehensive information on the Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 6, 4, 1, 27 and 6 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 7 and 2 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Genetic Disorders, Immunology, Toxicology, Respiratory, Cardiovascular, Gastrointestinal, Infectious Disease, Musculoskeletal Disorders and Undisclosed which include indications Multiple Myeloma (Kahler Disease), Melanoma, Solid Tumor, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Alzheimer's Disease, Breast Cancer, Charcot-Marie-Tooth Disease Type II, Charcot-Marie-Tooth Disease, Chemotherapy Induced Peripheral Neuropathy, Colorectal Cancer, Diffuse Large B-Cell Lymphoma, Glioblastoma Multiforme (GBM), Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Multiple Sclerosis, Non-Small Cell Lung Cancer, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Triple-Negative Breast Cancer (TNBC), Chronic Lymphocytic Leukemia (CLL), Colon Cancer, Follicular Lymphoma, Idiopathic Pulmonary Fibrosis, Leukemia, Mantle Cell Lymphoma, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Rheumatoid Arthritis, Squamous Cell Carcinoma, Systemic Lupus Erythematosus, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Adenoid Cystic Carcinoma (ACC), Amyotrophic Lateral Sclerosis, Anal Cancer, Anaplastic Astrocytoma, Autoimmune Disorders, B-Cell Non-Hodgkin Lymphoma, Basal Cell Carcinoma (Basal Cell Epithelioma), Bile Duct Cancer (Cholangiocarcinoma), Burkitt Lymphoma, Cervical Cancer, Charcot-Marie-Tooth Disease Type I A, CNS Lymphoma, Crohn's Disease (Regional Enteritis), Cutaneous T-Cell Lymphoma, Diabetic Neuropathic Pain, Diastolic Heart Failure, Dilated Cardiomyopathy, Distal Symmetric Polyneuropathy, Fibrosis, Gastric Cancer, Gliosarcoma, Head And Neck Cancer Squamous Cell Carcinoma, High-Grade Glioma, Human Papillomavirus (HPV) Associated Cancer, Huntington Disease, Liver Cancer, Lung Adenocarcinoma, Lupus Nephritis, Lymphoma, Marginal Zone B-cell Lymphoma, Metastatic Melanoma, Mycosis Fungoides, Myelodysplastic Syndrome, Myeloproliferative Disorders, Neuroblastoma, Neuroendocrine Tumors, Neurology, Neuropathic Pain (Neuralgia), Non-Hodgkin Lymphoma, Non-Small Cell Lung Carcinoma, NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma), Pediatric Diffuse Intrinsic Pontine Glioma, Penile Cancer, Polycystic Kidney Disease, Rectal Cancer, Recurrent Medulloblastoma, Rett Syndrome, Sepsis, Small-Cell Lung Cancer, Systemic Sclerosis (Scleroderma), Tauopathies, Ulcerative Colitis, Unspecified, Unspecified B-Cell Lymphomas, Unspecified Cancer and Vulvar Cancer.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98)
- The report reviews Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics and enlists all their major and minor projects
- The report assesses Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics

Reasons to Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Overview
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Companies Involved in Therapeutics Development
Annji Pharmaceutical Co Ltd
ATP Biopharm
Augustine Therapeutics
Avstera Therapeutics Inc
Beijing Konruns Pharmaceutical Co Ltd
Bristol-Myers Squibb Co
Chong Kun Dang Pharmaceutical Corporation
Convalife
CStone Pharmaceuticals Co Ltd
Curis Inc
Eikonizo Therapeutics Inc
Guangdong Zhongsheng Pharmaceutical Co Ltd
Hillstream BioPharma Inc
Jubilant Therapeutics Inc
Kancera AB
Karus Therapeutics Ltd
KYAN Therapeutics Inc
Medivir AB
Merck & Co Inc
Mycovia Pharmaceuticals Inc
OnKure Inc
Oryzon Genomics SA
Quimatryx SL
Shuttle Pharmaceuticals Inc
SK Biopharmaceuticals Co Ltd
Starwise Therapeutics LLC
Suzhou GenHouse Pharmaceutical Co Ltd
Tenaya Therapeutics Inc
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Drug Profiles
ACY-1083 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ACY-738 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ACY-775 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ADV-300 - Drug Profile
Product Description
Mechanism Of Action
AJ-302 - Drug Profile
Product Description
Mechanism Of Action
History of Events
AJ-303 - Drug Profile
Product Description
Mechanism Of Action
History of Events
AVS-100 - Drug Profile
Product Description
Mechanism Of Action
History of Events
C-1A - Drug Profile
Product Description
Mechanism Of Action
citarinostat - Drug Profile
Product Description
Mechanism Of Action
History of Events
CKD-504 - Drug Profile
Product Description
Mechanism Of Action
History of Events
CKD-506 - Drug Profile
Product Description
Mechanism Of Action
History of Events
CKD-510 - Drug Profile
Product Description
Mechanism Of Action
History of Events
CKD-L - Drug Profile
Product Description
Mechanism Of Action
CS-3003 - Drug Profile
Product Description
Mechanism Of Action
History of Events
CVL-608 - Drug Profile
Product Description
Mechanism Of Action
History of Events
CX-1026 - Drug Profile
Product Description
Mechanism Of Action
History of Events
EKZ-001 - Drug Profile
Product Description
Mechanism Of Action
History of Events
fimepinostat - Drug Profile
Product Description
Mechanism Of Action
History of Events
GH-36 - Drug Profile
Product Description
Mechanism Of Action
HDAC6 - Drug Profile
Product Description
Mechanism Of Action
HSB-510 - Drug Profile
Product Description
Mechanism Of Action
History of Events
JBI-097 - Drug Profile
Product Description
Mechanism Of Action
History of Events
JBI-802 - Drug Profile
Product Description
Mechanism Of Action
History of Events
KA-2507 - Drug Profile
Product Description
Mechanism Of Action
History of Events
KAN-0440262 - Drug Profile
Product Description
Mechanism Of Action
History of Events
KYAN-001 - Drug Profile
Product Description
Mechanism Of Action
History of Events
MPT-0B291 - Drug Profile
Product Description
Mechanism Of Action
MPT-0G211 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Nexturastat A - Drug Profile
Product Description
Mechanism Of Action
QTX-125 - Drug Profile
Product Description
Mechanism Of Action
History of Events
QTX-153 - Drug Profile
Product Description
Mechanism Of Action
History of Events
remetinostat - Drug Profile
Product Description
Mechanism Of Action
History of Events
ricolinostat - Drug Profile
Product Description
Mechanism Of Action
History of Events
RTSV-5 - Drug Profile
Product Description
Mechanism Of Action
History of Events
SE-7552 - Drug Profile
Product Description
Mechanism Of Action
History of Events
SKLB-23bb - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Inhibit HDAC1 and HDAC6 for Breast Cancer - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Inhibit HDAC1, HDAC3 and HDAC6 for Lung Adenocarcinoma - Drug Profile
Product Description
Mechanism Of Action
Small Molecule to Inhibit HDAC6 for Charcot-Marie-Tooth Disease Type II A - Drug Profile
Product Description
Mechanism Of Action
Small Molecule to Inhibit HDAC6 for Melanoma - Drug Profile
Product Description
Mechanism Of Action
Small Molecule to Inhibit HDAC6 for Sepsis - Drug Profile
Product Description
Mechanism Of Action
Small Molecules for Charcot-Marie-Tooth Disease - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit HDAC-6 for Autoimmune Disorders, Charcot-Marie-Tooth Disease and Pancreatic Cancer - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit HDAC6 for Alzheimer's Disease - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Inhibit HDAC6 for Glioblastoma - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit HDAC6 for Immunology and Oncology - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit HDAC6 for Oncology - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit HDAC6 for Rett Syndrome - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Inhibit HDAC6 for Unspecified Indications - Drug Profile
Product Description
Mechanism Of Action
History of Events
SP-259 - Drug Profile
Product Description
Mechanism Of Action
Synthetic Peptides to Inhibit HDAC6 for Solid tumor, Fibrosis and Neurology - Drug Profile
Product Description
Mechanism Of Action
TN-301 - Drug Profile
Product Description
Mechanism Of Action
History of Events
vorinostat - Drug Profile
Product Description
Mechanism Of Action
History of Events
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Dormant Products
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Product Development Milestones
Featured News & Press Releases
Jul 06, 2022: Tenaya Therapeutics publishes preclinical data in science translational medicine detailing discovery of HDAC6 inhibitor for treatment of heart failure
May 20, 2022: Tenaya Therapeutics to present preclinical data on TN-301 HDAC6 inhibitor at European Society of Cardiology Heart Failure 2022 Conference
Apr 26, 2022: Jubilant Therapeutics doses first patient in phase I/II trial evaluating JBI-802, dual inhibitor of LSD1 and HDAC6, in patients with advanced solid tumors
Mar 11, 2022: AnnJi Pharmaceutical’s HDAC6 selective inhibitor received “Grass Roots” support program award sponsored by Boehringer Ingelheim, Taiwan
Feb 01, 2022: Hillstream BioPharma announces acceptance of abstract at AACR 2022 annual meeting highlighting HSB-510, a novel quatramer-based, first-in-class dual inhibitor of HDAC6 and PI3K-delta downregulating c-myc expression
Jan 06, 2022: Jubilant Therapeutics announces FDA clearance of IND for JBI-802, a novel dual LSD1 and HDAC6 inhibitor, for treatment of solid tumors
Nov 18, 2021: Results from investigator-initiated phase II clinical study of remetinostat in patients with squamous cell carcinoma published
Sep 30, 2021: Jubilant Therapeutics announces successful completion of Pre-IND meeting with FDA for its novel dual LSD1 and HDAC6 inhibitor JB1-802
Aug 16, 2021: Medivir strengthens the business development potential of remetinostat through renegotiated multi-party agreement
Aug 12, 2021: Positive data from the remetinostat phase II study in basal cell carcinoma published in Clinical Cancer Research
Aug 06, 2021: Medivir: First-in-class histone deacetylase inhibitor gel shows promise for the treatment of patients with basal cell carcinoma
Jul 29, 2021: Shuttle Pharma awarded a new patent for selective inhibitors for cancer treatment
Jul 13, 2021: Tenaya Therapeutics unveils preclinical research supporting product candidate for rare and prevalent heart disease indications at ESC Heart Failure 2021
May 20, 2021: Positive results from investigator-initiated phase II clinical study of remetinostat in patients with squamous cell carcinoma published
Dec 07, 2020: Jubilant Therapeutics announces efficacy and biomarker data at 62nd ASH Annual Meeting for its Novel Dual LSD1-HDAC6 Inhibitor for the Treatment of Hematological Cancers
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by Annji Pharmaceutical Co Ltd, 2022
Pipeline by ATP Biopharm, 2022
Pipeline by Augustine Therapeutics, 2022
Pipeline by Avstera Therapeutics Inc, 2022
Pipeline by Beijing Konruns Pharmaceutical Co Ltd, 2022
Pipeline by Bristol-Myers Squibb Co, 2022
Pipeline by Chong Kun Dang Pharmaceutical Corporation, 2022
Pipeline by Convalife, 2022
Pipeline by CStone Pharmaceuticals Co Ltd, 2022
Pipeline by Curis Inc, 2022
Pipeline by Eikonizo Therapeutics Inc, 2022
Pipeline by Guangdong Zhongsheng Pharmaceutical Co Ltd, 2022
Pipeline by Hillstream BioPharma Inc, 2022
Pipeline by Jubilant Therapeutics Inc, 2022
Pipeline by Kancera AB, 2022
Pipeline by Karus Therapeutics Ltd, 2022
Pipeline by KYAN Therapeutics Inc, 2022
Pipeline by Medivir AB, 2022
Pipeline by Merck & Co Inc, 2022
Pipeline by Mycovia Pharmaceuticals Inc, 2022
Pipeline by OnKure Inc, 2022
Pipeline by Oryzon Genomics SA, 2022
Pipeline by Quimatryx SL, 2022
Pipeline by Shuttle Pharmaceuticals Inc, 2022
Pipeline by SK Biopharmaceuticals Co Ltd, 2022
Pipeline by Starwise Therapeutics LLC, 2022
Pipeline by Suzhou GenHouse Pharmaceutical Co Ltd, 2022
Pipeline by Tenaya Therapeutics Inc, 2022
Dormant Products, 2022

List of Figures
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

Report Title: Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update


Your Details
Valid Invalid number

SELECT A FORMAT

ADD TO CART BUY NOW

Related Report

2023 What's Next for Vietnam Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for Vietnam Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for Venezuela Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for Venezuela Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for US Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for US Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for Uruguay Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for Uruguay Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for United Arab Emirates Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for United Arab Emirates Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for Ukraine Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for Ukraine Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM